Skip to Main Content

Paper Details

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
Br J Cancer
2
2023
BRCA1/2, CD38, CD38 high B cells, CD40, HRR, HRR defects, PARP, PD-L1, PEComa, Rare cancers, advanced, advanced solid cancers, cancers, cholangiocarcinoma, homologous recombination repair gene, neuroendocrine, gallbladder and endometrial cancer, olaparib, patients, perivascular epithelioid cell, rare cancers, tumour
Author NameAffiliation
Mandy L BallingerSchool of Clinical Medicine, University of NSW
Mandy L BallingerGarvan Institute of Medical Research
Mandy L BallingerSchool of Clinical Medicine, University of NSW
Mandy L BallingerGarvan Institute of Medical Research
Anthony M JoshuaThe Kinghorn Cancer Centre, St Vincent's Hospital
Anthony M JoshuaSchool of Clinical Medicine, University of NSW
Anthony M JoshuaGarvan Institute of Medical Research
David M ThomasThe Kinghorn Cancer Centre, St Vincent's Hospital
David M ThomasGarvan Institute of Medical Research
David M ThomasUniversity of New South Wales
David M ThomasThe Kinghorn Cancer Centre, St Vincent's Hospital
David M ThomasGarvan Institute of Medical Research
David M ThomasUniversity of New South Wales
  • 1 - 13

Datasets

Release 1.2